Medical specialists from Canada tagged as investigators in clinical trials studying Neoplasms, Plasma Cell
Total 36 results
-
Anna NikonovaSeen in:
- Quebec, Montreal, McGill University Health Centre (MUHC) - The Montreal General Hospital (MGH) - Cedars Cancer Centre
Trials:- NCT05556616 (Principal Investigator)
Conditions: -
Annette E. HaySeen in:
- Ontario, Kingston, Kingston Health Sciences Centre
Trials:- NCT04071457 (Principal Investigator)
Conditions: -
Anthony J. ReimanSeen in:
- New Brunswick, Saint John, Atlantic Health Sciences Corporation-Saint John Regional Hospital
Trials:- NCT04071457 (Principal Investigator)
Conditions: -
Anthony Reiman, MDSeen in:
- New Brunswick, Saint John, Saint John Regional Hospital (Horizon Health Network)
Trials:- NCT03421132 (Principal Investigator)
Conditions: -
Ariah J. SchattnerSeen in:
- Ontario, Oshawa, Lakeridge Health Oshawa
Trials:- NCT04071457 (Principal Investigator)
Conditions: -
Arleigh McCurdySeen in:
- Ontario, Ottawa, GSK Investigational Site
- Ontario, Ottawa, The Ottawa Hospital
Trials:- NCT04484623 (Principal Investigator)
- NCT03421132 (Principal Investigator)
Conditions: -
Chaim Shustik, MDSeen in:
- Quebec, Montréal, McGill University Health Centre
Trials:- NCT03421132 (Sub-Investigator)
Conditions: -
Christine ChenSeen in:
- Ontario, Toronto, Princess Margaret Cancer Centre
- Ontario, Toronto, Princess Margaret Hospital
- Ontario, Toronto, Princess Margaret Hospital (Ontario)
Trials:- NCT04666038 (Principal Investigator)
- NCT02343042 (Principal Investigator)
-
Christopher P. VennerSeen in:
- British Columbia, Vancouver, BCCA-Vancouver Cancer Centre
Trials:- NCT04071457 (Principal Investigator)
Conditions: -
Christopher VennerSeen in:
- British Columbia, Vancouver, British Columbia Cancer Agency Vancouver Centre
Trials:- NCT03215030 (Principal Investigator)
Conditions: -
Darrell WhiteSeen in:
- Nova Scotia, Halifax, GSK Investigational Site
- Nova Scotia, Halifax, Queen Elizabeth II Health Sciences Center
- Nova Scotia, Halifax, Queen Elizabeth II Health Sciences Centre
Trials:- NCT04126200 (Principal Investigator)
- NCT03421132 (Principal Investigator)
- NCT02343042 (Principal Investigator)
Conditions: -
Dina Khalaf, MDSeen in:
- Ontario, Hamilton, McMaster - Juravinski Cancer Centre
Trials:- NCT02649790 (Principal Investigator)
-
Donna Reece, MDSeen in:
- Ontario, Toronto, Princess Margaret Cancer Centre
- Ontario, Toronto, Princess Margaret Cancer Research Center/University Health Network
Trials:- NCT03421132 (Principal Investigator)
- NCT05227144 (Principal Investigator)
Conditions: -
Emilie Lemieux-BlanchardSeen in:
- Montreal, GSK Investigational Site
- Quebec, Montreal, Centre de recherche du CHUM
Trials:- NCT03215030 (Principal Investigator)
- NCT04484623 (Principal Investigator)
Conditions: -
Hira MianSeen in:
- Ontario, Hamilton, Buland Mangukia
- Ontario, Hamilton, Juravinski Cancer Centre
Trials:- NCT03215030 (Principal Investigator)
- NCT03421132 (Principal Investigator)
Conditions: -
Irwindeep SandhuSeen in:
- Alberta, Edmonton, Cross Cancer Institute / University of Alberta
- Alberta, Edmonton, GSK Investigational Site
Trials:- NCT04126200 (Principal Investigator)
- NCT02343042 (Principal Investigator)
Conditions: -
John Storring, MDSeen in:
- Quebec, Montréal, McGill University Health Centre
Trials:- NCT03421132 (Sub-Investigator)
Conditions: -
Karen Yee, MDSeen in:
- Ontario, Toronto, Princess Margaret Cancer Center
- Ontario, Toronto, Princess Margaret Cancer Centre
Trials:- NCT05275439 (Principal Investigator)
- NCT02649790 (Principal Investigator)
Conditions:- Acute Myeloid Leukemia;
- Myelodysplastic Syndromes;
- Acute Myeloid Leukemia (AML);
- Metastatic Colorectal Cancer (mCRC);
- Metastatic Castration-Resistant Prostate Cancer (mCRPC);
- Relapsed/Refractory Multiple Myeloma (RRMM);
- Higher-Risk Myelodysplastic Syndrome (HR-MDS);
- Newly Diagnosed Intermediate/High-Risk MDS
-
Kevin SongSeen in:
- British Columbia, Vancouver, GSK Investigational Site
- British Columbia, Vancouver, Vancouver General Hospital
Trials:- NCT04126200 (Principal Investigator)
- NCT03421132 (Principal Investigator)
Conditions: -
Martha LouzadaSeen in:
- Ontario, London, Victoria Hospital
Trials:- NCT03215030 (Principal Investigator)
Conditions: -
Michael Sebag, MDSeen in:
- Quebec, Montréal, McGill University Health Centre
Trials:- NCT03421132 (Principal Investigator)
Conditions: -
Michel PavicSeen in:
- Quebec, Sherbrooke, Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont
- Quebec, Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
- Quebec, Sherbrooke, Centre hospitalier universitaire de Sherbrooke (CHUS)
- Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke CHUS
Trials:- NCT04879329 (Principal Investigator)
- NCT05590377 (Principal Investigator)
- NCT02488967 (Principal Investigator)
- NCT05220098 (Principal Investigator)
Conditions:- Urothelial Carcinoma;
- Multiple Myeloma;
- Stage IIIA Breast Cancer;
- Stage IB Breast Cancer;
- Stage IIA Breast Cancer;
- Stage IIB Breast Cancer;
- Stage IIIC Breast Cancer;
- Estrogen Receptor Negative;
- HER2/Neu Negative;
- Progesterone Receptor Negative;
- Triple-Negative Breast Carcinoma;
- Breast Adenocarcinoma;
- Unresectable Locally Advanced or Metastatic Cancer
-
Nizar Bahlis, MDSeen in:
- Alberta, Calgary, Tom Baker Cancer Centre
Trials:- NCT03421132 (Principal Investigator)
Conditions: -
Phillip KuruvillaSeen in:
- Ontario, Brampton, William Osler Health Center
Trials:- NCT05590377 (Principal Investigator)
Conditions: -
Rajiv Samant, MDSeen in:
- Ontario, Ottawa, The Ottawa Hospital
Trials:- NCT00800059 (Principal Investigator)
Conditions:
Clinical Trials on Neoplasms, Plasma Cell
-
IRCCS Centro di Riferimento Oncologico della BasilicataCelgene CorporationCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell LeukemiaUnited States
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)WithdrawnRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnPlasma Cell Myeloma | Plasma Cell Leukemia in RemissionUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell MyelomaUnited States